Tracking Changes in Oral Health-Related Quality of Life Before, During, and After Radiotherapy in Tongue Squamous Cell Carcinoma: A Case Series.

IF 2 3区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Patient preference and adherence Pub Date : 2025-08-20 eCollection Date: 2025-01-01 DOI:10.2147/PPA.S539093
Irna Sufiawati, Novi Indriyani, Imme Kris Wicaksono, Emailsa Denta
{"title":"Tracking Changes in Oral Health-Related Quality of Life Before, During, and After Radiotherapy in Tongue Squamous Cell Carcinoma: A Case Series.","authors":"Irna Sufiawati, Novi Indriyani, Imme Kris Wicaksono, Emailsa Denta","doi":"10.2147/PPA.S539093","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tongue squamous cell carcinoma (TSCC) is the most common type of oral cancer. Effective and patient-centered management is essential to reduce mortality, improve survival, and enhance oral health-related quality of life (OHRQoL).</p><p><strong>Purpose: </strong>To assess OHRQoL and pain levels in TSCC patients across radiotherapy phases and the impact of supportive care on treatment adherence and patient well-being.</p><p><strong>Case report: </strong>Four patients presented with painful, non-healing tongue ulcers of 4-8 months' duration and were referred to the Oral Medicine Clinic. All were diagnosed with TSCC and underwent radiotherapy. OHRQoL and pain levels were assessed using the oral health impact profile-14 (OHIP-14) and visual analogue scale (VAS), before, during, after radiotherapy. Common intraoral side effects included oral candidiasis, mucositis, and xerostomia, all of which impacted patients' comfort and adherence to ongoing treatment.</p><p><strong>Case management: </strong>Management of radiotherapy-induced side effects included nystatin oral suspension, 0.025% hyaluronic acid mouthwash, diphenhydramine HCl, and artificial saliva gel. Individualized care plans were developed based on patient feedback and treatment tolerance. All patients demonstrated clinical improvement in oral lesions within 1-7 weeks. OHIP-14 and VAS scores improved before treatment (OHIP-14: 30-44; VAS: 9), during treatment (OHIP-14: 27-36; VAS: 8), and one month afterward (OHIP-14: 10-15; VAS: 1-5).</p><p><strong>Conclusion: </strong>The integration of proactive and personalized supportive oral care during radiotherapy can significantly improve OHRQoL and reduce pain levels, facilitating better treatment adherence and patient satisfaction. These findings support the importance of multidisciplinary collaboration and proactive symptom management in TSCC care.</p>","PeriodicalId":19972,"journal":{"name":"Patient preference and adherence","volume":"19 ","pages":"2525-2534"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375360/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Patient preference and adherence","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PPA.S539093","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tongue squamous cell carcinoma (TSCC) is the most common type of oral cancer. Effective and patient-centered management is essential to reduce mortality, improve survival, and enhance oral health-related quality of life (OHRQoL).

Purpose: To assess OHRQoL and pain levels in TSCC patients across radiotherapy phases and the impact of supportive care on treatment adherence and patient well-being.

Case report: Four patients presented with painful, non-healing tongue ulcers of 4-8 months' duration and were referred to the Oral Medicine Clinic. All were diagnosed with TSCC and underwent radiotherapy. OHRQoL and pain levels were assessed using the oral health impact profile-14 (OHIP-14) and visual analogue scale (VAS), before, during, after radiotherapy. Common intraoral side effects included oral candidiasis, mucositis, and xerostomia, all of which impacted patients' comfort and adherence to ongoing treatment.

Case management: Management of radiotherapy-induced side effects included nystatin oral suspension, 0.025% hyaluronic acid mouthwash, diphenhydramine HCl, and artificial saliva gel. Individualized care plans were developed based on patient feedback and treatment tolerance. All patients demonstrated clinical improvement in oral lesions within 1-7 weeks. OHIP-14 and VAS scores improved before treatment (OHIP-14: 30-44; VAS: 9), during treatment (OHIP-14: 27-36; VAS: 8), and one month afterward (OHIP-14: 10-15; VAS: 1-5).

Conclusion: The integration of proactive and personalized supportive oral care during radiotherapy can significantly improve OHRQoL and reduce pain levels, facilitating better treatment adherence and patient satisfaction. These findings support the importance of multidisciplinary collaboration and proactive symptom management in TSCC care.

舌鳞状细胞癌放疗前、放疗中、放疗后口腔健康相关生活质量的跟踪变化:一个病例系列
背景:舌鳞癌(TSCC)是最常见的口腔癌。有效和以患者为中心的管理对于降低死亡率、提高生存率和提高口腔健康相关生活质量(OHRQoL)至关重要。目的:评估放疗期间TSCC患者的OHRQoL和疼痛水平,以及支持治疗对治疗依从性和患者幸福感的影响。病例报告:4例患者出现疼痛,持续4-8个月的不愈合舌溃疡,被转介到口腔医学诊所。所有患者均被诊断为TSCC并接受放疗。在放疗前、放疗期间和放疗后,采用口腔健康影响量表-14 (o嘻哈-14)和视觉模拟量表(VAS)评估患者的OHRQoL和疼痛水平。常见的口腔内副作用包括口腔念珠菌病、粘膜炎和口干,所有这些都影响患者的舒适度和对持续治疗的依从性。病例处理:放疗引起的副作用处理包括制霉素口服混悬液、0.025%透明质酸漱口水、盐酸苯海拉明、人工唾液凝胶。根据患者反馈和治疗耐受性制定个性化护理计划。所有患者在1-7周内均表现出口腔病变的临床改善。治疗前(OHIP-14: 30-44; VAS: 9)、治疗中(OHIP-14: 27-36; VAS: 8)和治疗后1个月(OHIP-14: 10-15; VAS: 1-5) OHIP-14和VAS评分均有改善。结论:放疗期间结合积极主动和个性化的支持性口腔护理可显著提高患者的OHRQoL,减轻疼痛程度,提高治疗依从性和患者满意度。这些发现支持多学科合作和主动症状管理在TSCC护理中的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Patient preference and adherence
Patient preference and adherence MEDICINE, GENERAL & INTERNAL-
CiteScore
3.60
自引率
4.50%
发文量
354
审稿时长
6-12 weeks
期刊介绍: Patient Preference and Adherence is an international, peer reviewed, open access journal that focuses on the growing importance of patient preference and adherence throughout the therapeutic continuum. The journal is characterized by the rapid reporting of reviews, original research, modeling and clinical studies across all therapeutic areas. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal. As of 1st April 2019, Patient Preference and Adherence will no longer consider meta-analyses for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信